Neumora Therapeutics (NMRA) Preferred Stock Liabilities (2022 - 2023)
Neumora Therapeutics' quarterly Preferred Stock Liabilities came in at $843.7 million in Q2 2023, little changed quarter-over-quarter from $843.7 million in Q1 2023.
Neumora Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $843.7 million in Q2 2023.
- For the quarter ending Q2 2023, Preferred Stock Liabilities changed N/A year-over-year to $843.7 million; the trailing twelve-month figure through Jun 2023 stood at $843.7 million (changed N/A YoY), and the FY2022 full-year result was $843.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2023 stood at $843.7 million, roughly flat from $843.7 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $843.7 million in Q4 2022, with the low at $817.1 million in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 843.69 Mn |
| Mar 31, 2023 | 843.69 Mn |
| Dec 31, 2022 | 843.69 Mn |
| Sep 30, 2022 | 817.10 Mn |